Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Kornélia Polyák, Michalina Janiszewska et al.|Nature|2016Cited by 629
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory CancersPer Hydbring, Piotr Siciński, Yinan Wang et al.|Cancer Cell|2017Cited by 98
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 InhibitorGary M. Gallego, Sajiv K. Nair, Cynthia L. Palmer et al.|Journal of Medicinal Chemistry|2025Cited by 4